Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031837 · ClinicalTrials.gov registry record · Phase 3
Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
A Phase 3 study, sponsored by Gary Morrow.
- Terminated
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00031837: Clinical Trial Phase 3 study, sponsored by Gary Morrow.
NCT00031837 is a Phase 3 study that was terminated before completion, run by Gary Morrow. The registered enrollment target is 400 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00031837, a Phase 3 study, was terminated before completion, sponsored by Gary Morrow.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Anticoagulants such as dalteparin may help prevent blood clots in patients being treated with gemcitabine for unresectable or metastatic pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without dalteparin in treating patients who have unresectable or metastatic pancreatic cancer.
Interventions
- PROCEDURE quality-of-life assessment
- DRUG gemcitabine hydrochloride
- DRUG dalteparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2002-10 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Why NCT00031837 stopped before completion
NCT00031837 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 3 interventions - of which quality-of-life assessment is the first listed.
NCT00031837 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00031837 about?
NCT00031837 is a clinical study titled "Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Anticoagulants such as dalteparin may help prevent blood clots in patients being treated with gemcitabine for unresectable or metastatic pancreatic cancer...
What is the current status of trial NCT00031837?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2002-10. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00031837?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), gemcitabine hydrochloride (DRUG), dalteparin (DRUG).
Who is sponsoring clinical trial NCT00031837?
This trial is sponsored by Gary Morrow, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00031837's enrollment target sits among peer trials
400 922nd of 2000 higher than 1,039 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia